Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Early Phase 1

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(5)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07319195Early Phase 1Recruiting

Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)

Role: collaborator

NCT07437287Phase 2Not Yet Recruiting

Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

Role: collaborator

NCT04888312Phase 1Active Not Recruiting

Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients

Role: lead

NCT05934539Phase 1Unknown

ALG.APV-527 First-in-human Study

Role: collaborator

NCT04144842Phase 1Completed

Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017

Role: lead

NCT03782467Phase 1Completed

Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

Role: lead

NCT02379741Phase 1Completed

ADC-1013 First-in-Human Study

Role: lead

All 7 trials loaded